FDA Approves Cefepime-Zidebactam Injection

By
Kathryn Wighton
June 3, 2026

Conexiant

Share

1

The FDA approved cefepime and zidebactam for treating complicated urinary tract infections in adults.
2

The approval is based on the phase 3 ENHANCE-1 trial, which involved 530 patients across multiple countries.
3

Cefepime and zidebactam achieved a composite clinical cure rate of 89%, compared to 68% for meropenem.
4

The treatment combines a fourth-generation cephalosporin with a non-beta-lactam antibacterial and beta-lactamase inhibitor.
5

Cefepime and zidebactam received Priority Review, Fast Track, and Qualified Infectious Disease Product designations from the FDA.

Original Source(s)

Conexiant

FDA Approves Cefepime-Zidebactam Injection

by Kathryn Wighton
June 3, 2026

Related Content

Frontiers In Medicine

Association between baseline-stratified trajectory subgroups of serum albumin and outcomes in critically ill patients with early sepsis-associated acute kidney injury: a retrospective study

by Qiang Gao, Xinwu Lai, Yu Tian, Tingting Wang, Xiangde Zheng, An Zhang
May 29, 2026

Conexiant

Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.